CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.00% for the 3-month period ending 2025-10-31, per its 10-Q filed 2025-12-15.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-12-15
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-10-31 was 0.00%.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-07-31 was 4.48%, a 13.42% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-01-31 was 4.49%, a 21.35% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-10-31 was 4.49%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month |
|---|---|---|---|
| 2025-10-31 | 0.00% 10-Q · filed 2025-12-15 | ||
| 2024-07-31 | 4.48% 10-Q · filed 2025-09-15 | ||
| 2024-01-31 | 4.49% 10-Q · filed 2025-03-17 | ||
| 2023-10-31 | 4.49% 10-Q · filed 2024-12-16 | ||
| 2023-07-31 | 3.95% 10-Q · filed 2024-09-13 | ||
| 2023-01-31 | 3.70% 10-Q · filed 2024-03-15 | ||
| 2022-10-31 | 0.00% 10-Q · filed 2023-12-13 | 2.87% 10-Q · filed 2023-12-13 | |
| 2022-07-31 | 2.87% 10-Q · filed 2022-09-12 | ||
| 2021-10-31 | 0.00% 10-Q · filed 2021-12-13 | ||
| 2021-07-31 | 0.82% 10-Q · filed 2022-09-12 | ||
| 2021-01-31 | 0.12% 10-Q · filed 2022-03-15 | ||
| 2020-10-31 | 0.27% 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | 0.39% 10-Q · filed 2021-09-13 | ||
| 2019-10-31 | 1.57% 10-Q · filed 2020-12-14 | 1.57% 10-Q · filed 2020-12-14 | |
| 2019-07-31 | 0.00% 10-Q · filed 2020-09-14 | ||
| 2018-10-31 | 2.78% 10-Q · filed 2019-12-16 | ||
| 2018-07-31 | 2.82% 10-Q · filed 2019-09-16 | ||
| 2018-01-31 | 1.98% 10-Q · filed 2019-03-18 | ||
| 2017-10-31 | 0.00% 10-Q · filed 2018-12-17 | 1.98% 10-Q · filed 2017-12-15 | 1.98% 10-Q · filed 2018-12-17 |
| 2017-07-31 | 1.98% 10-Q · filed 2018-09-14 | ||
| 2015-01-31 | 0.00% 10-Q · filed 2016-03-16 | ||
| 2012-10-31 | 0.90% 10-Q · filed 2013-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |